Last reviewed · How we verify
PD1-T cells
PD1-T cells are a type of immunotherapy that uses genetically modified T cells to target and kill cancer cells.
PD1-T cells are a type of immunotherapy that uses genetically modified T cells to target and kill cancer cells. Used for Relapsed or refractory B-cell non-Hodgkin lymphoma, Relapsed or refractory acute lymphoblastic leukemia.
At a glance
| Generic name | PD1-T cells |
|---|---|
| Also known as | PD-1 monoclonal antibody-activated peripheral blood T-lymphocyte |
| Sponsor | Tianjin Medical University Cancer Institute and Hospital |
| Drug class | CAR-T cell therapy |
| Target | PD-1 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
PD1-T cells work by removing the brakes on the immune system, allowing T cells to recognize and attack cancer cells. This is achieved by modifying T cells to express a chimeric antigen receptor (CAR) that targets the PD-1 receptor on cancer cells, thereby activating the immune system to attack the cancer.
Approved indications
- Relapsed or refractory B-cell non-Hodgkin lymphoma
- Relapsed or refractory acute lymphoblastic leukemia
Common side effects
- Cytokine release syndrome
- Neutropenia
- Anemia
- Thrombocytopenia
- Infections
Key clinical trials
- Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (PHASE2)
- Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors (PHASE1)
- Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer (PHASE1)
- A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection (PHASE1, PHASE2)
- Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma (PHASE2)
- A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (PHASE1)
- Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma (PHASE2)
- Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PD1-T cells CI brief — competitive landscape report
- PD1-T cells updates RSS · CI watch RSS
- Tianjin Medical University Cancer Institute and Hospital portfolio CI